Страна: Австралия
Язык: английский
Источник: Department of Health (Therapeutic Goods Administration)
rizatriptan benzoate, Quantity: 14.53 mg (Equivalent: rizatriptan, Qty 10 mg)
Medsurge Pharma Pty Ltd
rizatriptan benzoate
Tablet, orally disintegrating
Excipient Ingredients: crospovidone; aspartame; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; calcium silicate; mannitol; Flavour
Oral
6, 2, 3
(S4) Prescription Only Medicine
RIZATRIPTAN-Au is indicated for the acute treatment of migraine attacks with or without aura.
Visual Identification: White, round, flat, bevel-edged tablet embossed with "IZ 10" on one side and plain on the other side; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius
Licence status A
2015-02-19
1 Rizatriptan‐Au CMI 200610 v1.1 RIZATRIPTAN-AU ORODISPERSIBLE TABLETS _Rizatriptan benzoate_ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you start using RIZATRIPTAN-AU. This leaflet answers some common questions about RIZATRIPTAN-AU. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking RIZATRIPTAN-AU against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT RIZATRIPTAN- AU ARE USED FOR RIZATRIPTAN-AU are used to relieve the headache pain and other symptoms of migraine attacks. RIZATRIPTAN-AU do not work for other types of headaches. Migraine is an intense, throbbing, typically one-sided headache. It often includes nausea, vomiting, sensitivity to light, and sensitivity to sound. Some people may have visual symptoms before the headache, called an aura. An aura can include flashing lights or wavy lines. Migraine attacks last anything from two hours to two days and they can return frequently. The severity and frequency of migraine attacks may vary. Migraine occurs in about one out of every 10 people. It is three times more common in women than men. Six out of ten migraine sufferers have their first attack before the age of 20. There is no single cause of migraine. It tends to run in families. Certain things, singly or in combination, can trigger migraine attacks in some people. Some of these triggers are: certain foods or drinks, for example, cheese and other dairy products, chocolate, citrus fruit, caffeine, alcohol (especially red wine) stress, anger, worry changes in routine, for example, under or over sleeping, missing a meal, change in diet bright light or loud noises hormonal changes in women, for example, during menstrual periods Прочитать полный документ
RIZATRIPTAN-AU _ _ PRODUCT INFORMATION 1 AUSTRALIAN PRODUCT INFORMATION – RIZATRIPTAN-AU (RIZATRIPTAN BENZOATE) ORODISPERSIBLE TABLETS 1 NAME OF THE MEDICINE Rizatriptan benzoate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains either 7.265 mg or 14.53 mg of rizatriptan benzoate (corresponding to 5 mg or 10 mg of rizatriptan, respectively). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM 5 mg orodispersible tablet - White, round, flat, bevel-edged tablet embossed with “IZ 5” on one side and plain on the other side. 10 mg orodispersible tablet - White, round, flat, bevel-edged tablet embossed with “IZ 10” on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS RIZATRIPTAN-AU is indicated for the acute treatment of migraine attacks with or without aura. 4.2 D OSE AND METHOD OF ADMINISTRATION The recommended dose is 10 mg. Clinical experience has shown that this dose provides the optimal clinical benefit. Onset of relief (i.e., reduction of headache pain to mild or none) can occur within 30 minutes after dosing. _Re-dosing: _Doses should be separated by at least 2 hours; no more than 30 mg should be taken in any 24-hour period. • _for headache recurrence within 24 hours: _If headache returns after relief of the initial attack, further doses may be taken. The above dosing limits should be observed. • _after non-response: _The effectiveness of a second dose for treatment of the same attack, when an initial dose is ineffective, has not been examined in controlled trials. o Clinical studies have shown that patients who do not respond to treatment of an attack are still likely to respond to treatment for subsequent attacks. _Patients _ _receiving _ _propranolol: _ Plasma concentrations of rizatriptan may be increased by concomitant administration of propranolol (see Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS)_. _The 10 mg dose is not appropriate for these RIZATRIPT Прочитать полный документ